In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease

Table 2 Mixed-effects regression models of longitudinal change in composite cognitive scores across baseline amyloid accumulation stages

	Delayed recall composite score		Executive function composite score		Immediate learning composite score		PACC3 composite score
	Estimate	t-statistic	Estimate	t-statistic	Estimate	t-statistic	Estimate	t-statistic
Intercept	− 0.338	− 0.542	2.829***	4.557	− 0.051	− 0.078	0.567	0.934
Age	− 0.021**	− 2.683	− 0.06***	− 7.765	− 0.029***	− 3.555	− 0.04***	− 5.344
Gender	0.482***	5.05	0.103	1.069	0.565***	5.655	0.528***	5.684
Education	0.054**	3.214	0.039*	2.344	0.056**	3.184	0.063***	3.826
Follow-up time, years	0.026***	3.889	− 0.018**	− 3.294	0.027***	4.218	− 0.001	− 0.256
Stage I	− 0.043	− 0.149	0.451	1.624	0.114	0.378	0.393	1.43
Stage II	0.099	0.356	− 0.043	− 0.164	0.21	0.731	0.209	0.799
Stage III	− 0.113	− 0.479	− 0.297	− 1.326	− 0.166	− 0.68	− 0.44*	− 1.981
Stage IV	0.171	0.56	− 0.433	− 1.397	0.114	0.364	− 0.08	− 0.281
Follow-up time × stage I	− 0.06	− 1.593	− 0.027	− 0.897	− 0.037	− 0.99	− 0.032	− 1.007
Follow-up time × stage II	0.047	1.227	− 0.088**	− 2.712	0.019	0.5	− 0.014	− 0.425
Follow-up time × stage III	− 0.105***	− 3.377	− 0.084***	− 3.348	− 0.079**	− 2.598	− 0.056*	− 2.132
Follow-up time × stage IV	− 0.299***	− 5.514	− 0.027	− 0.596	− 0.255***	− 4.783	− 0.188***	− 4.043

Unstandardized estimates are presented with t-statistics. *p < .05, **p < .01, ***p < .001. For interactions between the follow-up time in years and stage, the stage 0 group acts as a reference. Random intercepts for participants are included to account for multiple measurements

ISSN: 1758-9193